If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 171 - 180 of 293

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression

This study is a Phase I/II, first-in-human, open-label dose-escalation study of BT5528 given as a single agent (Parts A-1 and B-1) and in combination with nivolumab (Parts A-2 and B-2). There are two parts to this study: Part A, dose escalation and Part B, dose expansion.
Protocol No
BICYCLE-BT5528-100

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Protocol No
NRG-GU010-GUIDANCE